-
12/17/2013
PAION AG to issue approx. 2.8 million shares at EUR 1.80 per share in capital increase with subscription rights
-
11/26/2013
PAION grants licence for Turkey to add to R-Pharm territory
-
11/25/2013
PAION AG announces positive End-of-Phase II Meeting with FDA for Remimazolam in procedural sedation
-
11/14/2013
PAION AG reports headline data of ONO's phase II/III trial - Remimazolam meets primary endpoint and shows good safety data
-
10/30/2013
PAION AG grants license to R-Pharm for Remimazolam in Russia (CIS)
-
10/28/2013
PAION AG grants license to Hana Pharm for Remimazolam in South Korea
-
07/02/2013
PAION signs exclusive option agreement with Hana Pharm for Remimazolam in South Korea
-
03/06/2013
PAION decide to put on hold the launch of Remifentanil in Germany